Labcorp isn’t alone in developing alternatives to the more invasive cerebrospinal fluid tests and expensive PET brain scans currently used to spot the biological changes associated with Alzheimer’s ...
BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo for Labcorp is displayed on a screen on the floor of the NYSE in New York By Deena Beasley (Reuters) - ...
Please provide your email address to receive an email when new articles are posted on . Labcorp Diagnostics announced the launch of the first widely accessible blood test that provides direct evidence ...
Add Yahoo as a preferred source to see more of our stories on Google. The new test measures the risk of preeclampsia with up to 90% sensitivity and 90% specificity, according to Labcorp. Photo by ...
(Reuters) - Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...
(RTTNews) - Labcorp (LH) Wednesday has introduced the pTau-217/Beta Amyloid 42 Ratio test, a blood-based biomarker designed to aid in Alzheimer's diagnosis. Offering accuracy comparable to PET imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results